Kyntra Bio (KYNB) Total Current Liabilities (2014 - 2026)

Kyntra Bio has reported Total Current Liabilities for 13 years, with the latest figure at $28.1 million in Q1 2026.

• Quarterly Total Current Liabilities fell 61.69% year-over-year to $28.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.1 million (down 61.69% YoY) and the FY2025 annual result came in at $29.2 million, down 78.06% from the prior year.
• Total Current Liabilities fell to $28.1 million in Q1 2026 per KYNB's latest filing, from $29.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $273.6 million in Q4 2022 and troughed at $28.1 million in Q1 2026.
• A 5-year average of $169.9 million and a median of $194.1 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 52.88% in 2022, then sank 81.12% in 2025.
• Over 5 years, Total Current Liabilities stood at $273.6 million in 2022, then fell by 20.43% to $217.7 million in 2023, then sank by 38.76% to $133.3 million in 2024, then plunged by 78.06% to $29.2 million in 2025, then slipped by 3.86% to $28.1 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $28.1 million, $29.2 million, and $36.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.